You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

Filtered By:
18 Items
Cancer Type: Hematologic, Leukemia - Acute Promyelocytic (APL)     
Intent: Curative
Drugs Used:
amsacrine,
cytarabine,
tretinoin (ATRA) (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Leukemia - Acute Myeloid (AML)     
Intent: Curative
Drugs Used:
amsacrine,
cytarabine
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Lymphoma - Hodgkin     
Intent: Palliative
Funding:
ODB - General Benefit
    lomustine
ODB - General Benefit
    etoposide - oral capsules
ODB - General Benefit
    prednisone
ODB - General Benefit
    chlorambucil
... Show more tags
Drugs Used:
lomustine,
etoposide,
prednisone,
chlorambucil
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL), Lymphoma - Non-Hodgkin's High Grade, Lymphoma - Non-Hodgkin's Intermediate Grade, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
ODB - General Benefit
    chlorambucil
ODB - General Benefit
    prednisone
... Show more tags
Drugs Used:
chlorambucil
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - Previously Untreated Chronic Lymphocytic Leukemia
ODB - General Benefit
    chlorambucil
... Show more tags
Drugs Used:
chlorambucil,
oBINutuzumab
... Show more tags
Quick Link(s):
Regimen Monograph
Nov 2018
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    chlorambucil
... Show more tags
Drugs Used:
oBINutuzumab,
chlorambucil
... Show more tags
Quick Link(s):
Regimen Monograph
Dec 2018
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab - Retreatment - Indolent Lymphoma
ODB - General Benefit
    chlorambucil
New Drug Funding Program
    Rituximab (SC) in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (SC) - Retreatment - Indolent Lymphoma
... Show more tags
Drugs Used:
riTUXimab,
chlorambucil,
riTUXimab (subcut)
... Show more tags
Quick Link(s):
Regimen Monograph
Oct 2018
Cancer Type: Hematologic, Lymphoma - Hodgkin     
Intent: Palliative
Funding:
ODB - General Benefit
    chlorambucil
ODB - General Benefit
    procarbazine
ODB - General Benefit
    prednisone
... Show more tags
Drugs Used:
chlorambucil,
vinBLAStine,
procarbazine,
prednisone
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
Exceptional Access Program
    everolimus - In combination with exemestane, for the treatment of hormone-receptor positive, HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
ODB Limited Use
    exemestane - In combination with everolimus, for the treatment of hormone-receptor positive HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
... Show more tags
Drugs Used:
everolimus,
exemestane
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019
Cancer Type: Breast     
Intent: Adjuvant
Funding:
ODB Limited Use
    exemestane - Sequential treatment of postmenopausal women with estrogen receptor-positive early breast cancer who have received 2-3 years of initial adjuvant tamoxifen therapy
... Show more tags
Drugs Used:
exemestane
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
ODB Limited Use
    exemestane - Hormonal treatment of metastatic breast cancer in hormone receptor positive postmenopausal women who have disease progression following tamoxifen therapy
... Show more tags
Drugs Used:
exemestane
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
Exceptional Access Program
    For the treatment of post-menopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative unresectable locally advanced breast cancer or metastatic breast cancer, according to clinical criteria
... Show more tags
Drugs Used:
exemestane (Unfunded),
palbociclib
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019